To assess the dynamics of various cytokines in people with HIV who transition from a three-drug regimen to a dolutegravir-based two-drug regimen, focusing on inflammation.
Key Findings:
No virological failure or transient low-level viremia was observed during the study.
At month 12, plasma concentrations of MIG increased from 2785 pg/mL to 2966 pg/mL (p = 0.017).
Plasma concentrations of IL-18 increased from 63.33 pg/mL to 75.10 pg/mL (p = 0.009).
IL-6 and IP-10 levels remained stable throughout the study period.
The increase in IL-18 was not correlated with changes in IL-18BP.
Interpretation:
Limitations:
The study had a small sample size of 35 participants.
The exploratory extension analysis was limited to a subset of 6 participants.
Conclusion:
Increased levels of IL-18 and MIG were observed at 12 months after switching to a two-drug regimen, while IL-6 and IP-10 levels remained stable.
